Amneal Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
November 6, 2020 6:10 AM ESTAmneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.16, $0.04 better than the analyst estimate of $0.12. Revenue for the quarter came in at $519 million versus the consensus estimate of $482.11 million.
Amneal delivered another strong quarter, providing further evidence that our Amneal 2.0 strategy is positioning the company... More
